Meropenem Dosing in Elderly Patients with Renal Impairment
For elderly patients (≥65 years) with impaired renal function, meropenem dosing must be adjusted based on creatinine clearance (CrCl) using the FDA-approved renal dosing table: for CrCl 26-50 mL/min give the full dose every 12 hours instead of every 8 hours; for CrCl 10-25 mL/min give half the recommended dose every 12 hours; and for CrCl <10 mL/min give half the recommended dose every 24 hours. 1
Critical First Step: Calculate Creatinine Clearance
Never rely on serum creatinine alone in elderly patients—this is the most dangerous error, as reduced muscle mass causes serum creatinine to dramatically underestimate renal impairment. 2, 3
Calculate creatinine clearance using the Cockcroft-Gault equation before every dosing decision, as renal function declines by approximately 1% per year after age 30-40, resulting in up to 40% reduction by age 70. 4, 2
For patients with extreme cachexia, severe obesity, or very low creatinine values where calculation formulas become unreliable, obtain direct GFR measurement using 51Cr-EDTA or inulin clearance. 2, 3
FDA-Approved Renal Dosing Algorithm
The following table from the FDA label provides the definitive dosing schedule: 1
For complicated skin/skin structure infections (standard dose 500 mg q8h) or intra-abdominal infections (standard dose 1 gram q8h):
- CrCl >50 mL/min: Give recommended dose every 8 hours
- CrCl 26-50 mL/min: Give recommended dose every 12 hours
- CrCl 10-25 mL/min: Give one-half recommended dose every 12 hours
- CrCl <10 mL/min: Give one-half recommended dose every 24 hours
For Pseudomonas aeruginosa infections: Use 1 gram every 8 hours as the baseline dose, then adjust intervals/amounts according to the same CrCl-based algorithm above. 1
Evidence Supporting Dose Reduction
Meropenem clearance is significantly reduced in elderly patients due to age-associated decline in renal function, with terminal half-life increasing from 0.81 hours in young adults to 1.27 hours in elderly patients (67-80 years). 5
Drug exposure (AUC) for meropenem is 158-286% higher in patients with impaired renal function receiving reduced doses compared to patients with normal renal function receiving regular doses, confirming that dose reduction is necessary but still results in adequate exposure. 6
Population pharmacokinetic studies demonstrate that creatinine clearance is the most significant covariate influencing meropenem clearance in elderly patients, with no direct independent effect of age beyond its impact on renal function. 7
Administration Considerations
Administer via intravenous infusion over 15-30 minutes, or as a bolus injection (5-20 mL) over 3-5 minutes for adult patients. 1
Extended infusions (3 hours) may optimize pharmacodynamic target attainment, particularly for resistant organisms (MIC >4 mg/L), but require careful monitoring in renally impaired patients to avoid toxicity. 7, 8
Safety Profile in Elderly and Renally Impaired
Meropenem has an excellent safety profile in elderly and renally impaired patients, with adverse event patterns similar to younger cohorts when appropriate dose adjustments are made. 9
Meropenem-related seizures are rare (0.1%), even in patients with renal impairment, which is notably safer than imipenem/cilastatin in this population. 9
No clinically significant changes in renal function indicators occur between baseline and end of treatment when proper dosing is followed. 9
Monitoring and Toxicity Prevention
Monitor for nephrotoxicity risk when trough concentrations approach ≥45 mg/L, which can occur with inadequate dose reduction in severe renal impairment. 8
Therapeutic drug monitoring (TDM) is particularly valuable in elderly patients with fluctuating renal function, as 64% of patients in real-world practice require dose modification from standard renal-adjusted regimens. 10
The strong inverse correlation (r = -0.7) between renal function and meropenem concentrations means that even small changes in CrCl can significantly impact drug exposure. 10
Common Pitfalls to Avoid
Do not use age alone to determine dosing—elderly patients with preserved renal function (CrCl >50 mL/min) should receive standard dosing intervals. 1, 7
Do not assume stable renal function—elderly patients are at high risk for acute changes in kidney function during illness, requiring reassessment of CrCl if clinical status changes. 4, 2
Avoid co-administration with nephrotoxic drugs (NSAIDs, aminoglycosides) that can further compromise renal function and alter meropenem clearance. 3
Do not use probenecid concurrently—it inhibits renal excretion of meropenem and is not recommended. 1